Maze Therapeutics (NASDAQ:MAZE) Insider Sells $52,437.07 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Phillips Courtney sold 1,981 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total transaction of $52,437.07. Following the sale, the insider directly owned 9,019 shares of the company’s stock, valued at approximately $238,732.93. This represents a 18.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

• On Thursday, September 3rd, Phillips Courtney sold 2,012 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12.

Maze Therapeutics Stock Performance

MAZE opened at $26.21 on Monday. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. The company’s 50 day simple moving average is $28.69 and its two-hundred day simple moving average is $31.06. Maze Therapeutics, Inc. has a 1-year low of $14.27 and a 1-year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). Analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Royal Bank of Canada lifted its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics in the 4th quarter valued at about $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 2nd quarter valued at about $48,000. Finally, Russell Investments Group Ltd. lifted its position in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Analyst Ratings Changes

Several research analysts have recently commented on MAZE shares. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.